CPT code 81325 represents full-gene sequencing of the peripheral myelin protein 22 (PMP22) gene, a molecular diagnostic test used to detect sequence variants that can cause inherited peripheral neuropathies. Nationally, this code captures a specialized laboratory service relevant for neuromuscular and genetic diagnostic workflows and influences coverage determinations, laboratory billing practices, and utilization monitoring for rare genetic conditions. Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code's clinical context, typical sites of service, and the kinds of documentation and service lines associated with molecular genetic testing. The publication summarizes payer coverage patterns and common modifier usage where available, highlights benchmark considerations for laboratory billing, and outlines the clinical scenarios that commonly drive use of full-gene PMP22 sequencing. Data gaps are noted as "Data not available in the input." The content is aimed at billing managers, laboratory directors, and policy analysts seeking a national perspective on coding and reimbursement implications for comprehensive PMP22 sequencing.